CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV

CNS Pharmaceuticals highlighted a new segment of "Behind the Mystery" focused on glioblastoma from The Balancing Act airing on Lifetime TV. The segment, live this morning, follows the unique story of a glioblastoma patient and clinical insights regarding the rare and difficult-to-treat disease from Dr. Sigmund Hsu, a member of the Scientific Advisory Board of CNS Pharmaceuticals. A re-airing of the segment is planned for October 23, 2020.

John Climaco, CEO of CNS Pharmaceuticals Says: "It is encouraging to see the Balancing Act feature bring awareness to such a devastating disease. Glioblastoma is one of the most aggressive primary brain cancers in adults, with approximately 13,000 new patients diagnosed each year in the U.S.—the highest diagnosis rate of all malignant brain tumors. At CNS, we are committed to our development efforts in glioblastoma." 

Related Posts

Subscribe Our Newsletter